- Home
- MOS vs EXEL Comparison
MOS vs EXEL Comparison
Compare MOS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- EXEL
- Stock Information
- Founded
- MOS 1987
- EXEL 1994
- Country
- MOS United States
- EXEL United States
- Employees
- MOS N/A
- EXEL N/A
- Industry
- MOS Agricultural Chemicals
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOS Industrials
- EXEL Health Care
- Exchange
- MOS Nasdaq
- EXEL Nasdaq
- Market Cap
- MOS 8.4B
- EXEL 9.4B
- IPO Year
- MOS 2004
- EXEL 2000
- Fundamental
- Price
- MOS $27.24
- EXEL $36.70
- Analyst Decision
- MOS Buy
- EXEL Buy
- Analyst Count
- MOS 12
- EXEL 18
- Target Price
- MOS $30.58
- EXEL $37.59
- AVG Volume (30 Days)
- MOS 6.2M
- EXEL 2.8M
- Earning Date
- MOS 04-30-2025
- EXEL 04-29-2025
- Dividend Yield
- MOS 3.23%
- EXEL N/A
- EPS Growth
- MOS N/A
- EXEL 170.77
- EPS
- MOS 0.55
- EXEL 1.76
- Revenue
- MOS $11,122,800,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- MOS $9.32
- EXEL $5.45
- Revenue Next Year
- MOS N/A
- EXEL $10.32
- P/E Ratio
- MOS $49.83
- EXEL $20.85
- Revenue Growth
- MOS N/A
- EXEL 18.50
- 52 Week Low
- MOS $22.48
- EXEL $20.14
- 52 Week High
- MOS $33.44
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- MOS 56.58
- EXEL 48.90
- Support Level
- MOS $26.64
- EXEL $36.71
- Resistance Level
- MOS $28.66
- EXEL $38.41
- Average True Range (ATR)
- MOS 0.76
- EXEL 1.10
- MACD
- MOS 0.17
- EXEL -0.18
- Stochastic Oscillator
- MOS 66.67
- EXEL 21.43
About MOS Mosaic Company (The)
Formed in 2004 by the combination of IMC Global and Cargill's fertilizer business, Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business, which the company acquired from Vale in 2018.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.